(Sharecast News) - Drugmaker GSK made two key updates on Monday, with positive phase III trial results for tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections, and a favourable regulatory opinion for a new prefilled syringe format of its shingles vaccine, Shingrix.
GSK and partner Spero Therapeutics said...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE